Top Page
Zentek
(NASDAQ:ZEN)
Zentek (ZEN) vs. iShares MSCI Canada ETF (EWC)
Zentek Business Overview & Revenue Model
Zentek Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 64.66K | 29.82K | 72.86K | 339.67K | 2.35K | 0.00 | Gross Profit |
| -2.21M | -385.06K | -780.48K | -275.04K | -124.44K | -24.88K | EBIT |
| -7.09M | -10.99M | -14.15M | -12.56M | -3.98M | -1.68M | EBITDA |
| -9.73M | -11.08M | -13.75M | -11.27M | -3.73M | -1.55M | Net Income Common Stockholders |
| -10.66M | -11.70M | -14.41M | -38.69M | -3.87M | -1.53M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 10.08M | 3.52M | 10.36M | 26.68M | 3.09M | 805.95K | Total Assets |
| 12.57M | 22.59M | 33.29M | 37.98M | 30.25M | 26.24M | Total Debt |
| 0.00 | 1.24M | 1.61M | 2.23M | 404.32K | 0.00 | Net Debt |
| -9.56M | -2.28M | -8.75M | -24.44M | -2.69M | -805.95K | Total Liabilities |
| 337.06K | 2.41M | 2.90M | 3.44M | 2.79M | 527.58K | Stockholders Equity |
| 12.23M | 20.17M | 30.38M | 34.55M | 27.46M | 25.71M |
| Cash Flow | Free Cash Flow | ||||
| -6.70M | -8.37M | -15.23M | -11.97M | -2.05M | -1.46M | Operating Cash Flow |
| -6.69M | -8.05M | -12.96M | -7.99M | -1.79M | -1.36M | Investing Cash Flow |
| 408.83K | 1.88M | -2.31M | -7.25M | -1.23M | -1.24M | Financing Cash Flow |
| 2.42M | -665.47K | -1.05M | 38.82M | 5.31M | 2.18M |
Zentek Technical Analysis
Zentek Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $257.38M | ― | -4.87% | ― | 7.84% | 82.16% | |
62 Neutral | C$125.55M | ― | -8.34% | ― | 0.69% | -95.27% | |
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
53 Neutral | C$68.05M | ― | -149.09% | ― | ― | -67.03% | |
45 Neutral | C$199.90M | ― | -108.05% | ― | ― | ― | |
43 Neutral | $208.62M | ― | -54.98% | ― | 92.38% | 12.79% | |
26 Underperform | C$119.95M | ― | 90.17% | ― | ― | -78.59% |
Zentek Corporate Events
Zentek Ltd. has received a purchase order from Dexterra Group Inc. for its ZenGUARD™ Enhanced Air Filters to be used at the Forensic Services and Coroner’s Complex in Toronto. This order signifies a growing adoption of Zentek’s innovative air filtration technology in Canada, aligning with the company’s vision of enhancing indoor air quality and reducing emissions through nanotechnology. The collaboration with Dexterra, a leader in facilities management, is expected to further promote the use of Zentek’s products across Canada, potentially impacting the company’s market presence and stakeholder interests positively.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Neutral.
Zentek’s stock is significantly impacted by financial struggles, particularly persistent negative profitability and cash flow issues. While technical analysis suggests some potential for stabilization and corporate events offer promising developments, the company’s high financial risks and valuation concerns weigh heavily on its attractiveness as an investment.
To see Spark’s full report on TSE:ZEN stock, click here.
Zentek has completed the first phase of its $1.1 million contract with the Government of Canada to develop an avian influenza countermeasure using its multivalent aptamer technology. The project, which aims to enhance Canada’s response to the global H5N1 outbreak, has moved to the testing phase after successful in vitro experiments. The collaboration with McMaster University has resulted in a lead candidate that meets the performance metrics set by the Canadian government, demonstrating efficacy comparable to monoclonal antibodies. This development positions Zentek as a key player in the field of innovative medical countermeasures, with potential implications for stakeholders in public health and defense sectors.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Neutral.
Zentek’s overall stock score is significantly impacted by financial struggles, particularly persistent negative profitability and cash flow issues. While technical analysis suggests some potential for stabilization and corporate events offer promising developments, the company’s high financial risks and valuation concerns weigh heavily on its attractiveness as an investment.
To see Spark’s full report on TSE:ZEN stock, click here.
Zentek Ltd. has announced the sale of its property at 24 Corporate Court, Guelph, which houses its corporate office and laboratory space, as part of a strategic review to support long-term business goals. The sale, valued at $2.5 million, includes a leaseback agreement allowing Zentek to maintain operations at the site until January 31, 2026, ensuring no disruption to its operations or staff. The completion of the sale is expected by May 15, 2025, with relocation plans to be communicated later.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Underperform.
Zentek’s overall score reflects significant financial challenges, primarily due to persistent negative profitability and cash flow issues. While technical indicators and recent corporate events offer some hope, valuation concerns and potential financial liabilities from tax reassessments weigh heavily. Addressing these financial weaknesses will be crucial for improving the company’s stock performance.
To see Spark’s full report on TSE:ZEN stock, click here.
Zentek Ltd. has successfully completed testing of its ZenARMOR™ nano-pigment technology in military-grade, chromate-free corrosion protection aerospace paint systems, in collaboration with the National Research Council of Canada. The tests demonstrated the effectiveness of ZenARMOR™ in preventing corrosion of aluminum alloy AA2024-T3. Following this success, Zentek has entered into a new collaboration with Jazeera Paints Company to further evaluate and develop ZenARMOR™ in their existing product lines. This partnership aims to leverage nanotechnology to enhance corrosion protection products, aligning with Jazeera Paints’ commitment to innovation in the construction industry across the Gulf Cooperation Council and the Middle East and North Africa region.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Underperform.
Zentek’s overall score reflects significant financial challenges, primarily due to persistent negative profitability and cash flow issues. While technical indicators and recent corporate events offer some hope, valuation concerns and potential financial liabilities from tax reassessments weigh heavily. Addressing these financial weaknesses will be crucial for improving the company’s stock performance.
To see Spark’s full report on TSE:ZEN stock, click here.
Zentek Ltd. has announced a strategic partnership with Filtration Solutions Industrial Co. (FSCO) to manufacture and distribute ZenGUARD™ Enhanced Air Filters in the Gulf Cooperation Council region. This collaboration will leverage Zentek’s proprietary graphene-silver-based technology to improve viral filtration efficiency in HVAC filters, addressing the growing demand for advanced materials and sustainable technologies in the region. The partnership aligns with the GCC’s strategic vision to become a global hub for advanced materials and manufacturing, and it is expected to enhance indoor air quality while reducing emissions and operational costs in public and private sectors.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Underperform.
Zentek’s overall score is heavily influenced by its financial struggles, with persistent losses and negative cash flows posing significant risks. While technical analysis suggests some long-term stability, valuation concerns due to unprofitability and mixed corporate events further impact the stock’s attractiveness.
To see Spark’s full report on TSE:ZEN stock, click here.
Zentek Ltd. has successfully closed a non-brokered private placement of debenture units, raising $2,000,000 in gross proceeds. The debenture units consist of secured convertible debentures and warrants, with the debentures maturing in 2028 and convertible into common shares at a specified price. The proceeds from this offering will be used for working capital and general corporate purposes, potentially strengthening Zentek’s financial position and supporting its ongoing operations and strategic initiatives. This move could enhance Zentek’s industry positioning by providing the necessary capital to further develop its technology and expand its market reach.
Spark’s Take on TSE:ZEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:ZEN is a Neutral.
Zentek’s overall score reflects significant financial challenges with persistent negative profitability and cash flow issues. While recent technical indicators show some positive trends, valuation remains a concern due to unprofitability. Corporate events provide a mix of challenges and opportunities, with promising product development offset by financial liabilities from tax reassessments.
To see Spark’s full report on TSE:ZEN stock, click here.
Zentek Ltd. announced that the Canada Revenue Agency (CRA) has completed an audit of the company’s 2018 and 2019 renunciation of Canadian exploration expenses (CEE) related to flow-through financings. The audit resulted in a reclassification of approximately $507,000 of the renounced expenses for 2018, leading to a tax assessment of $59,693. Zentek anticipates a similar reclassification for 2019 and has committed to indemnifying subscribers for tax liabilities arising from disallowed renunciations, with a maximum liability expected to be around $527,000. This development may impact Zentek’s financial obligations and its stakeholders, particularly those involved in the flow-through financings.
Zentek Ltd. has successfully completed shelf-life efficacy testing for its ZenGUARD™ Enhanced Air Filters, demonstrating that the product maintains its viral filtration efficiency over a 20-month period. This achievement is crucial for the commercialization of the filters as a Class I medical device, ensuring compliance with medical device regulations and confirming the product’s reliability and safety for stakeholders.
Zentek Ltd. has announced a US$30 million at-the-market offering in the United States, with Rodman & Renshaw LLC acting as the exclusive sales agent. The proceeds from this offering will be used for corporate purposes, and the sales will be conducted on the Nasdaq Capital Markets or other recognized U.S. marketplaces, excluding Canadian markets.
Zentek’s subsidiary, Albany Graphite Corp., has announced significant results from its thermal purification testwork using a fluidized bed reactor. The process demonstrated the ability to achieve 99.9991% purity in graphite and recover rare earth elements as by-products, enhancing Zentek’s potential in the battery and nuclear graphite markets.